Sara A. Hurvitz, MD

Sara A. Hurvitz, MD, discusses some of the current important questions for the field of HER2-positive breast cancer now and highlights which of these unanswered questions she hopes are addressed soon.

A review of fam-trastuzumab deruxtecan nxki shows how it has become a standard of care for patients with metastatic breast cancer that is HER2-positive.

In season 4, episode 2 of Targeted Talks, Sara A. Hurvitz, MD, discusses key advances in the HER2-positive breast cancer space and interesting ongoing research, namely trastuzumab deruxtecan.

Before closing out their discussion on HER2+ breast cancer, expert oncologists share excitement for emerging treatment strategies and ongoing clinical trials.

A broad review of CNS-related clinical trial data in the setting of HER2+ breast cancer and concurrent brain metastases.

A brief discussion on treatment options available for patients with HER2+ metastatic breast cancer and brain metastases who progress on the HER2CLIMB regimen.

Centering discussion on a patient case of HER2+ breast cancer with brain metastases, experts consider optimal treatment regimens in this setting.

Focusing on the HER2CLIMB regimen, experts consider appropriate treatment options for patients with HER2+ metastatic breast cancer in the third-line setting and beyond.

Expert oncologists share brief notes on their real-world experience managing HER2+ metastatic breast cancer with trastuzumab deruxtecan.

Comprehensive discussion on the presence and management of interstitial lung disease in patients being treated for HER2+ metastatic breast cancer.

Shared insight on the DESTINY-Breast03 trial, which analyzed trastuzumab deruxtecan therapy in patients with HER2+ metastatic breast cancer.

Panelists provide a broad overview of treatment options available for patients diagnosed with HER2+ metastatic breast cancer.

A focused discussion on the subcutaneous formulation of trastuzumab and pertuzumab in patients with early-stage HER2+ breast cancer.

Shifting their focus to the adjuvant setting, expert panelists review the optimal selection of therapy following surgery in early-stage HER2+ breast cancer.

Comprehensive insight on the neoadjuvant treatment armamentarium for early-stage HER2+ breast cancer and the appropriate selection of specific agents.

Centering discussion on a patient case of early-stage HER2+ breast cancer, expert oncologists consider when it is appropriate to utilize neoadjuvant therapy.

Sara Hurvitz, MD, provides insight on the potential role of amcenestrant in the treatment of HR+ breast cancer in the future.

An expert in breast oncology shares her thoughts on the importance of the AMEERA-5 findings to the evolving treatment landscape for HR+ breast cancer.

Sara Hurvitz, MD, reviews clinical trial data on amcenestrant, an orally administered endocrine therapy, in patients with ER+/HER2- breast cancer as shown in the AMEERA trials.

Sara Hurvitz, MD, discusses the therapeutic landscape for HR+ advanced breast cancer and considerations for treatment selection.

Sara Hurvitz, MD, provides an overview of HR+ breast cancer.

Sara A. Hurvitz, MD, discusses sequencing the current therapies for patients with HER2-positive breast cancer.

A key opinion leader discusses how the role tucatinib is evolving in the management of HER2-positive metastatic breast cancer.

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses response to abemaciclib (Verzenio) in the neoMONARCH trial at the 2018 San Antonio Breast Cancer Symposium.

Sarah Hurvitz, MD, gives an overview of the neoMONARCH trial in hormone receptor-positive, HER2-negative breast cancer.

Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses the results of a study looking at pembrolizumab (Keytruda) in patients with triple-negative breast cancer (TNBC).